Summary & Overview
HCPCS Level II J8705: Topotecan, Oral, 0.25 mg
HCPCS Level II code J8705 denotes oral topotecan, 0.25 mg, a cytotoxic chemotherapy agent used in oncology. As an HCPCS Level II drug code, J8705 identifies the specific oral pharmaceutical product for billing and pharmacy reimbursement and matters nationally because oral oncolytics increasingly shift medication delivery and cost responsibility from facility-administered infusions to pharmacy-dispensed therapies taken at home. Accurate coding of oral chemotherapies affects pharmacy benefit administration, medical claims processing, and patient cost-sharing across commercial and public payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and typical sites of service, plus guidance on what to expect in benchmarking and policy contexts. The publication outlines where J8705 appears in service lines, how payers commonly categorize oral oncolytics, and what benchmarks and policy updates typically influence coverage and reimbursement. Specific operational details, such as common modifiers and payer-specific rules, are summarized elsewhere in the full publication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J8705 represents topotecan, oral, 0.25 mg, an oral chemotherapeutic formulation of topotecan used in oncology treatment regimens. The service type is oral chemotherapy medication administration (pharmacy-dispensed medication). The typical site of service is outpatient pharmacy or clinic-dispensed oral chemotherapy for patient self-administration at home, with initial dispensing or counseling occurring in an outpatient clinic or specialty pharmacy setting.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with recurrent ovarian cancer is prescribed oral topotecan for palliative chemotherapy following platinum-resistant disease. The medication billed as J8705 (Topotecan, oral, 0.25 mg) is dispensed by the clinic or specialty pharmacy and administered by the patient at home. The clinical workflow begins with an oncology visit where the medical oncologist documents indication, dose, and cycle length; a chemotherapy order is entered into the electronic medical record; pre-treatment labs (complete blood count, renal and hepatic panels) are obtained within 72 hours; the pharmacy verifies dosing and prepares medication with appropriate counseling on administration, adverse effects, and contraception requirements. Nursing may provide patient education and perform phone follow-up for toxicity assessment during the first cycle. Clinic billing uses J8705 for the oral agent; relevant evaluation and management or infusion visit codes may be billed separately if applicable. Documentation includes diagnosis, regimen details, cycle number, dose per tablet, lot/batch of dispensed medication, patient counseling, and lab results supporting safe administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Service not covered by this payer/Not applicable | Rarely used; apply only if payer requires explicit code for non-covered service per policy |